Hazard ratios (HRs) and 95% confidence intervals (CIs) of herpes zoster among liver cirrhosis patients during the 1-, 3-, and 5-year follow-up periods from the index ambulatory visit or inpatient care in 1998–2005.

<p>Adjustments were made for patients’ gender, age, urbanization level, geographic region, monthly income, hypertension, diabetes, human immunodeficiency virus, organ transplantation, hepatitis B, hepatitis C, chronic renal failure, systemic lupus erythematous, rheumatoid arthritis, chronic obstructive pulmonary disease, cancer, and alcoholism.</p

Flow chart of the selection of study subjects and control subjects from the National Health Insurance Research Database in Taiwan.

<p>Flow chart of the selection of study subjects and control subjects from the National Health Insurance Research Database in Taiwan.</p

Demographic characteristics of selected patients, stratified by the presence/absence of liver cirrhosis in 1998–2005 (n<i> = </i>28,002).

<p>Footnote: SD, standard deviation; HIV, human immunodeficiency virus; SLE, systemic lupus erythematous; COPD, chronic obstructive pulmonary disease.</p><p>*The average exchange rate in was US$1.00 ≈ New Taiwan (NT)$32.6.</p

Herpes zoster-free survival rates for patient with liver cirrhosis and comparison groups in 1998

<p>–<b>2005.</b></p

Multivariate stratified analyses of the association of liver cirrhosis with herpes zoster. In each stratum, liver cirrhosis was not statistically associated with herpes zoster.

<p>Multivariate stratified analyses of the association of liver cirrhosis with herpes zoster. In each stratum, liver cirrhosis was not statistically associated with herpes zoster.</p

Hazard ratios (HRs) and 95% confidence intervals (CIs) of herpes zoster among liver cirrhosis patients during the 5-year follow-up period from the index ambulatory visit or inpatient care in 1998–2005.

<p>Adjustments are made for patients’ gender, age, urbanization level, geographic region, monthly income, hypertension, diabetes, human immunodeficiency virus, organ transplantation, hepatitis B, hepatitis C, chronic renal failure, systemic lupus erythematous, rheumatoid arthritis, chronic obstructive pulmonary disease, cancer, and alcoholism.</p

Table_3_Genetic alterations in peritoneal metastatic tumors predicted the outcomes for hyperthermic intraperitoneal chemotherapy.csv

IntroductionCytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are considered for patients with peritoneal metastasis (PM). However, patients selection that relies on conventional prognostic factors is not yet optimal. In this study, we performed whole exome sequencing (WES) to establish tumor molecular characteristics and expect to identify prognosis profiles for PM management. MethodsIn this study, blood and tumor samples were collected from patients with PM before HIPEC. Tumor molecular signatures were determined using WES. Patient cohort was divided into responders and non-responders according to 12-month progression-free survival (PFS). Genomic characteristics between the two cohorts were compared to study potential targets. ResultsIn total, 15 patients with PM were enrolled in this study. Driver genes and enriched pathways were identified from WES results. AGAP5 mutation was found in all responders. This mutation was significantly associated with better OS (p = 0.00652). ConclusionsWe identified prognostic markers that might be useful to facilitate decision-making before CRS/HIPEC.</p

Table_2_Genetic alterations in peritoneal metastatic tumors predicted the outcomes for hyperthermic intraperitoneal chemotherapy.csv

IntroductionCytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are considered for patients with peritoneal metastasis (PM). However, patients selection that relies on conventional prognostic factors is not yet optimal. In this study, we performed whole exome sequencing (WES) to establish tumor molecular characteristics and expect to identify prognosis profiles for PM management. MethodsIn this study, blood and tumor samples were collected from patients with PM before HIPEC. Tumor molecular signatures were determined using WES. Patient cohort was divided into responders and non-responders according to 12-month progression-free survival (PFS). Genomic characteristics between the two cohorts were compared to study potential targets. ResultsIn total, 15 patients with PM were enrolled in this study. Driver genes and enriched pathways were identified from WES results. AGAP5 mutation was found in all responders. This mutation was significantly associated with better OS (p = 0.00652). ConclusionsWe identified prognostic markers that might be useful to facilitate decision-making before CRS/HIPEC.</p

Image_1_Genetic alterations in peritoneal metastatic tumors predicted the outcomes for hyperthermic intraperitoneal chemotherapy.jpeg

IntroductionCytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are considered for patients with peritoneal metastasis (PM). However, patients selection that relies on conventional prognostic factors is not yet optimal. In this study, we performed whole exome sequencing (WES) to establish tumor molecular characteristics and expect to identify prognosis profiles for PM management. MethodsIn this study, blood and tumor samples were collected from patients with PM before HIPEC. Tumor molecular signatures were determined using WES. Patient cohort was divided into responders and non-responders according to 12-month progression-free survival (PFS). Genomic characteristics between the two cohorts were compared to study potential targets. ResultsIn total, 15 patients with PM were enrolled in this study. Driver genes and enriched pathways were identified from WES results. AGAP5 mutation was found in all responders. This mutation was significantly associated with better OS (p = 0.00652). ConclusionsWe identified prognostic markers that might be useful to facilitate decision-making before CRS/HIPEC.</p

Image_2_Genetic alterations in peritoneal metastatic tumors predicted the outcomes for hyperthermic intraperitoneal chemotherapy.jpeg

IntroductionCytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are considered for patients with peritoneal metastasis (PM). However, patients selection that relies on conventional prognostic factors is not yet optimal. In this study, we performed whole exome sequencing (WES) to establish tumor molecular characteristics and expect to identify prognosis profiles for PM management. MethodsIn this study, blood and tumor samples were collected from patients with PM before HIPEC. Tumor molecular signatures were determined using WES. Patient cohort was divided into responders and non-responders according to 12-month progression-free survival (PFS). Genomic characteristics between the two cohorts were compared to study potential targets. ResultsIn total, 15 patients with PM were enrolled in this study. Driver genes and enriched pathways were identified from WES results. AGAP5 mutation was found in all responders. This mutation was significantly associated with better OS (p = 0.00652). ConclusionsWe identified prognostic markers that might be useful to facilitate decision-making before CRS/HIPEC.</p